R501-21-6. Substance Use Disorder Treatment Programs

  (1) All substance use disorder treatment programs shall develop and implement a plan on how to support opioid overdose reversal.

  (2) Maintain proof of completion of the National Survey of Substance Abuse Treatment Services (NSSATS) annually.

  (3) Medication-assisted treatment (MAT) in substance use disorder programs shall:

  (a) maintain a program-wide counselor to MAT consumer ratio of: 1:50;

  (b) assure all consumers see a licensed practitioner that is authorized to prescribe controlled substances at least once yearly;

  (c) show proof of completion of federally required physician training for physicians prescribing buprenorphine;

  (d) admit consumers to the program and prescribe, administer or dispense medications only after the completion of a face-to-face visit with a licensed practitioner having authority to prescribe controlled substances who confirms opioid dependence. A licensed practitioner having authority to prescribe controlled substances must approve every subsequent dose increase prior to the change;

  (e) require all consumers admitted to the program to participate in random drug testing. Drug testing will be performed by the program a minimum of two times per month for the first three months of treatment, and monthly thereafter; except for a consumer whose documented lack of progress shall require more frequent drug testing for a longer period of time;

  (f) require that consumers participate in at least one counseling session per week for the first 90 days. Upon documented successful completion of this phase of treatment, consumers shall be required to participate in counseling sessions at least twice monthly for the next six months. Upon documented successful completion of nine months of treatment, consumers shall be seen by a licensed counselor at least monthly thereafter until discharge; and

  (g) require one hour of prescribing practitioner time at the program site each month for every ten MAT consumers enrolled.

  (4) MAT Programs prescribing, administering or dispensing Methadone (Opioid Treatment Programs) shall:

  (a) maintain Substance Abuse and Mental Health Services Administration (SAMHSA) certification and accreditation as an opioid treatment program.

  (b) comply with DSAMH Rule R523-10 Governing Methadone and other opioid treatment service providers;

  (c) employ a:

  (i) licensed physician who is an American Society of Addiction Medicine certified physician; or

  (ii) prescribing licensed practitioner who can document specific training in current industry standards regarding methadone treatment for opioid addictions; or

  (iii) prescribing licensed practitioner who can document specific training or experience in methadone treatment for opioid addictions; and

  (d) provide one nurse to dispense or administer medications for every 150 Methadone consumers dosing on an average daily basis.

  (5) Certified DUI Education Programs

  (a) Only programs certified with the Division of Substance Abuse and Mental Health (DSAMH) to provide Prime for Life education in accordance with and R523-11 shall provide court ordered DUI education.

  (b) Certified DUI education programs shall:

  (i) complete and maintain a substance use screening for each participant prior to providing the education course;

  (A) screenings may be shared between providers with client written consent.;

  (ii) provide a workbook to each participant to keep upon completion of the course;

  (iii) ensure at least 16 hours of course education; and

  (iv) provide separate classes for adults and youth.

  (c) Any violations of this rule section will be reported to DSAMH for evaluation of certification.

  (6) Justice Reform Initiative (JRI) Certified Programs shall operate in compliance with DSAMH rules 523-3 and 523-4.

  (a) JRI certified programs shall maintain a criminogenic screen/risk assessment for each justice involved client and separate clients into treatment groups according to level of risk assessed.

  (b) Providers shall complete screenings that assess both substance abuse and mental health comorbidity.

  (c) JRI programs shall treat, or refer to other DHS licensed programs that have obtained a justice certification from the DSAMH to treat the array of disorders noted in screenings.

  (d) Any violations of this rule section shall be reported to DSAMH for evaluation of certification.